Rintaro Noro

Summary

Affiliation: Nippon Medical School
Country: Japan

Publications

  1. pmc Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation
    Rintaro Noro
    Department of Pulmonary Medicine Infection and Oncology, Nippon Medical School, 1 1 5 Sendagi, Bunkyo ku, Tokyo 113 8602, Japan
    BMC Cancer 6:277. 2006
  2. doi request reprint Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model
    Akihiko Miyanaga
    Department of Internal Medicine, Division of Pulmonary Medicine, Infectious Diseases and Oncology, Nippon Medical School, 1 1 5 Sendagi, Bunkyo ku, Tokyo 113 8602, Japan
    Mol Cancer Ther 7:1923-30. 2008
  3. ncbi request reprint E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib
    Akihiko Miyanaga
    Department of Pulmonary Medicine Infection and Oncology, Nippon Medical School, 1 1 5 Sendagi, Bunkyo ku, Tokyo, Japan
    Oncol Rep 19:377-83. 2008
  4. doi request reprint Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression
    Rintaro Noro
    Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
    Cancer Sci 101:1424-30. 2010
  5. ncbi request reprint PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors
    Rintaro Noro
    Department of Pulmonary Medicine Infection and Oncology, Nippon Medical School, 1 1 5 Sendagi, Bunkyo ku, Tokyo 113 8602, Japan
    Int J Oncol 31:1157-63. 2007
  6. ncbi request reprint In vitro simulation study of individualized chemotherapy in lung cancer
    Cai Li
    Department of Pulmonary Medicine Infection and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
    J Nihon Med Sch 74:217-22. 2007
  7. ncbi request reprint Phase I/II study of paclitaxel + carboplatin for refractory or recurrent non-small cell lung cancer
    Akihiko Gemma
    Department of Pulmonary Medicine Infection and Oncology, Nippon Medical School, Tokyo, Japan
    Anticancer Res 26:3083-7. 2006
  8. pmc MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells
    Mengru Cao
    Department of Internal Medicine, Division of Pulmonary Medicine Infection and Oncology, Nippon Medical School, Tokyo 113 8603, Japan
    Int J Oncol 41:869-75. 2012
  9. pmc Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation
    Akihiko Miyanaga
    Department of Pulmonary Medicine and Oncology, Nippon Medical School, Tokyo, Japan
    BMC Cancer 13:262. 2013
  10. pmc Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database
    Akihiko Gemma
    The Fourth Department of Medicine, Nippon Medical School, 1 1 5, Sendagi, Bunkyo ku, Tokyo, 113 8602, Japan
    BMC Cancer 6:174. 2006

Collaborators

Detail Information

Publications13

  1. pmc Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation
    Rintaro Noro
    Department of Pulmonary Medicine Infection and Oncology, Nippon Medical School, 1 1 5 Sendagi, Bunkyo ku, Tokyo 113 8602, Japan
    BMC Cancer 6:277. 2006
    ..However, gefitinib-sensitive and prolonged stable-disease-defined tumors without EGFR gene mutation have also been reported...
  2. doi request reprint Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model
    Akihiko Miyanaga
    Department of Internal Medicine, Division of Pulmonary Medicine, Infectious Diseases and Oncology, Nippon Medical School, 1 1 5 Sendagi, Bunkyo ku, Tokyo 113 8602, Japan
    Mol Cancer Ther 7:1923-30. 2008
    ....
  3. ncbi request reprint E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib
    Akihiko Miyanaga
    Department of Pulmonary Medicine Infection and Oncology, Nippon Medical School, 1 1 5 Sendagi, Bunkyo ku, Tokyo, Japan
    Oncol Rep 19:377-83. 2008
    ..In patients with surgically resected NSCLC tumors, the EGFR mutation status and E-cadherin staining can select patients who will benefit from gefitinib therapy...
  4. doi request reprint Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression
    Rintaro Noro
    Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
    Cancer Sci 101:1424-30. 2010
    ..We conclude that combination therapy with SAHA and S-1 in lung cancer may be promising due to its potential to overcome S-1 resistance via modulation of 5-FU/S-1 sensitivity-associated biomarker (TS) by HDAC inhibitor...
  5. ncbi request reprint PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors
    Rintaro Noro
    Department of Pulmonary Medicine Infection and Oncology, Nippon Medical School, 1 1 5 Sendagi, Bunkyo ku, Tokyo 113 8602, Japan
    Int J Oncol 31:1157-63. 2007
    ....
  6. ncbi request reprint In vitro simulation study of individualized chemotherapy in lung cancer
    Cai Li
    Department of Pulmonary Medicine Infection and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
    J Nihon Med Sch 74:217-22. 2007
    ..With elucidation of additional drug sensitivity factors, selection of appropriate anticancer drugs by gene expression profiling may make it possible to increase the response rate in lung cancer chemotherapy...
  7. ncbi request reprint Phase I/II study of paclitaxel + carboplatin for refractory or recurrent non-small cell lung cancer
    Akihiko Gemma
    Department of Pulmonary Medicine Infection and Oncology, Nippon Medical School, Tokyo, Japan
    Anticancer Res 26:3083-7. 2006
    ..The median survival time was 12 months. This combination showed a promising clinical activity with mild toxicity and should be selected for the investigational arm of phase III trials to be compared with either docetaxel or pemetrexed...
  8. pmc MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells
    Mengru Cao
    Department of Internal Medicine, Division of Pulmonary Medicine Infection and Oncology, Nippon Medical School, Tokyo 113 8603, Japan
    Int J Oncol 41:869-75. 2012
    ..These findings suggest that miR-23a regulates TGF-β-induced EMT by targeting E-cadherin in lung cancer cells and may be useful as a new therapeutic target in NSCLC...
  9. pmc Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation
    Akihiko Miyanaga
    Department of Pulmonary Medicine and Oncology, Nippon Medical School, Tokyo, Japan
    BMC Cancer 13:262. 2013
    ..The EML4-ALK fusion gene occurs generally in NSCLC without mutations in epidermal growth factor receptor (EGFR) and KRAS...
  10. pmc Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database
    Akihiko Gemma
    The Fourth Department of Medicine, Nippon Medical School, 1 1 5, Sendagi, Bunkyo ku, Tokyo, 113 8602, Japan
    BMC Cancer 6:174. 2006
    ..It is consequently desirable to find more appropriate therapeutic opportunities based on informed insights. A molecular pharmacological analysis was undertaken to design an improved chemotherapeutic strategy for advanced lung cancer...
  11. doi request reprint Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion
    Kazuhiro Kitamura
    Division of Pulmonary Medicine, Infection and Oncology, Department of Internal Medicine, Nippon Medical School, 1 1 5 Sendagi, Bunkyo ku, Tokyo 113 8603, Japan
    Cancer Chemother Pharmacol 71:457-61. 2013
    ....
  12. doi request reprint A case of pneumocystis pneumonia associated with everolimus therapy for renal cell carcinoma
    Yoshinobu Saito
    Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, Japan
    Jpn J Clin Oncol 43:559-62. 2013
    ....
  13. ncbi request reprint [EGFR and gefitinib (Iressa)]
    Rintaro Noro
    Division of Pulmonary Medicine, Infectious Disease, and Oncology, Dept of Internal Medicine, Nippon Medical School, Tokyo, Japan
    Gan To Kagaku Ryoho 35:1076-9. 2008
    ..3%, in the USA(FDA Approval Letter). Further studies about the prediction of drug-induced interstitial lung disease including SNPs analyses of the EGFR gene and other related molecules...